Orchestra BioMed Holdings, Inc. OBIO

Rank #2406 · Nasdaq · $0.4B market cap

Audited by Ernst & Young LLP, no going-concern flag in the latest filing.

Score

20.4

P/E

-5.8

P/B

5.20

ROE

-89.7%

Op. Margin

-2437.5%

Debt Ratio

64%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Weak

P/E -5.8x, P/B 5.20x. Ranks in the top 78% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -89.7%. Ranks in the top 96% of the universe.

Safety ★★★★☆

Good

Debt ratio 64%. Ranks in the top 27% of the universe.

Growth ★☆☆☆☆

Weak

Revenue decline of 4.4% year over year. Ranks in the top 75% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2020	–	–	–	$0.0B	–	114
2021	–	$-0.0B	$-0.0B	$-0.0B	–	-161
2022	–	$-0.0B	$-0.0B	$-0.0B	–	-162
2023	$0.0B	$-0.0B	$-0.0B	$-0.0B	-924.3	-218
2024	$0.0B	$-0.1B	$-0.0B	$0.1B	-1866.2	52
2025	$0.0B	$-0.1B	$-0.1B	$0.1B	-2437.5	64